Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide|[sol]|anthracycline neoadjuvant regimen

Breast cancers represent a set of highly heterogeneous diseases (Weigelt et al, 2008; Sotiriou and Pusztai, 2009). Ongoing studies are pursuing the identification of the cell of origin as well as genetic and epigenetic changes or alterations in signalling pathways associated with each breast cancer subset. Currently, these molecular classifications are not routinely used in clinical practice and breast cancers are still commonly classified according to oestrogen receptor (ER), progesterone receptor (PR) and HER2 status. However, triple-negative (TN) cancer is phenotypically defined by the lack of expression of ERA, PR and the absence of HER2 overexpression and amplification. There are not yet any specifically targeted treatments for this type of breast cancer. Cytotoxic chemotherapy is therefore the only treatment in this group that accounts for ~15% of all breast cancers. Several sets of clinical data show an heterogeneity in TN cancers owing to different molecular alterations and/or supposed cells of origin (basal-like and claudin-low subtypes are the more frequent) (Guedj et al, 2011; Nik-Zainal et al, 2012). Breast cancer subgroups differ very widely in their individual chemotherapy susceptibility, notably through their different rates of tumour cell proliferation (Andre et al, 2005). Until now, breast cancers have derived only small benefits from dose intensification treatment although recent data suggest that some subgroups, including TN tumours, may be very sensitive to dose-dense alkylator-based chemotherapy (Andre and Pusztai, 2006; Gluz et al, 2008; Nieto and Shpall, 2009; Bonilla et al, 2010; Lehmann-Che et al, 2010; Silver et al, 2010; Vollebergh et al, 2011). Neoadjuvant chemotherapy was initially developed for non-resectable breast cancers, but is now widely used in localised breast cancer not eligible for breast conserving therapy (Rastogi et al, 2008). Such frontline treatment defines pathological complete response (pCR, absence of infiltrating tumour in breast and lymph nodes) as the key endpoint, predicting long-term survival especially in patients with ERA-negative or TN tumours (Liedtke et al, 2008; von Minckwitz et al, 2012b). Several studies have demonstrated that high-grade and ERA-negative tumours achieve higher pCR rates than other subgroups (Guarneri et al, 2006; Caudle et al, 2010; Huober et al, 2010; Jones et al, 2010). Although the benefit of chemotherapy is not restricted to the latter, pCR is, in today’s practice,the best mean to identify patients highly responsive to a specific regimen. We have previously demonstrated that for locally advanced tumours treated with a frontline cyclophosphamide–anthracyclin (AC) dose-dense regimen (Cottu et al, 1999), only tumours with inactivating mutations in the P53 tumour suppressor reached pCR (Bertheau et al, 2002, 2007). Yet, several studies have pointed out that although TN cancers are often initially chemo-sensitive, they usually present an early relapse with a generally poor prognosis (Miller et al, 2005; Foulkes et al, 2010; von Minckwitz et al, 2011). Here, we report the long-term overall survival (OS) of a prospectively followed cohort of patients treated with our dose-dense regimen. We then compared our data with those from a companion cohort of patients treated with a conventional taxane-containing regimen. We observed significant differences in the survival rate of patients with (TN) cancers, urging for the use of AC dose intensification, rather than taxanes, in these subsets. Two hundred and sixty-seven patients with LABCs were treated in our breast disease unit. Ninety-nine patients were treated with SIM, whereas 168 patients received EC-T chemotherapy regimen. Median follow-up time from initiation of chemotherapy was 127 months for patients in the SIM arm (range 23–248) and 52 months for patients in the EC-T arm (range 10–97). Baseline patients and tumour features showed significantly more frequent T4 size and high histological grade in patients treated with the SIM protocol (Table 1a). Triple-negative tumours represented 23% and 25% of cases, respectively (Table 1b). Pathological response was assessed in all patients who underwent surgery (100% in SIM and 98% in EC-T). This dose-intensive anthracycline-based regimen was manageable in regards of toxicity despite pronounced myelotoxicity (Cottu et al, 1999). We first studied the predictive factors for pathological pCR. It was assessed in 99 patients (100%) in the SIM group and 165 (98%) in the EC-T group (Table 2). HER2 overexpression had no influence on pCR in both protocol groups. ER-negative tumours were more likely to achieve pCR than ER-positive tumours, both in SIM (14 out of 31 patients (45%) vs 2 out of 61 (3%)) and, to a lesser extent, in EC-T (13 out of 55 (24%) vs 6 out of 110 (5%)). Interaction between ER-negative tumour patients and the type of protocol (SIM vs EC-T) reached borderline significance, with a P-value of 0.099. Similarly, TN tumours were associated with non-statistically significantly higher pCR rates, than non-TN tumours in both SIM (10 out of 21 (48%) vs 6 out of 70 (9%)) and to a lesser extent in EC-T (10 out of 41 (24%) vs 9 out of 123 (3.7%)), although interaction between response in TN tumours and the type of protocol was negative (P=0.27). In the SIM protocol, the OS rate at 7 years was the same for patients with TN tumours as for patients with non-TN tumours, respectively 76% and 71%, P=0.78. Conversely, in the EC-T protocol, the OS at 7 years was worse for patients with TN tumours than for patients with non-TN tumours, respectively 65% vs 75%, P=0.001 (Figure 2C and D; Supplementary Figure C and D). Using the non-TN patients treated with EC-T as the standard, there is a fourfold (HR=3.98, 95% CI (1.69–9.37)) increase in relapse risk in the first 2 years in TN patients treated with EC-T (P=0.002) compared with the non-TN ones (Table 3). Non-TN patients treated by SIM had a higher, although non-significant, risk of relapse than those treated by EC-T before 2 years (HR=2.09, 95% CI (0.93–4.68), P=0.075). TN patients treated with SIM had a significantly lower risk of recurrence after 2 years compared with those treated with EC-T (HR=0.25, 95% CI (0.07–0.86), P=0.028). Similar results were observed for OS, although the difference between SIM and EC-T was not significant (Table 3). This retrospective analysis of patients from a single institution treated with two distinct neoadjuvant regimens yielded unexpected and impressive results that may provide important clues for TN breast cancer chemotherapy. We demonstrate that dose intensification is a major independent variable in the outcome of TN LABC. Therefore, these observations suggest that the SIM regimen is better suited than EC-T for TN LABC. Despite the higher prevalence of poor prognostic factors in the SIM-treated group, and the fact that 23 EC-T-treated patients received trastuzumab theoretically favouring the EC-T group, pCR and 7-year survival rates were similar in both populations. As in most other neoadjuvant studies (Nieto and Shpall, 2009; Silver et al, 2010), both SIM and EC-T preferentially triggered pCR in high-grade ER-negative tumours and pCR was very strongly associated with long-term survival (data not shown). Indeed, the SIM regimen was significantly more potent in yielding pCR and long-term DFS rate in TN tumours (Tables 2 and 3; Figure 2A and C; Supplementary Figure A and C). On the contrary, in ER-positive patients, the heterogeneity of endocrine treatment between the two regimens did not allow strong conclusions on survival to be drawn. In TN tumours, the adjusted survival analysis shows a difference between the two treatments. The key observation from this study is the presence of a long-term survival plateau of 70–80% for TN advanced tumours. Importantly in our study, whereas only 48% of patients with TN LABC tumours reached pCR (Table 3), 75% experienced long-term survival (Figure 2C; Supplementary Figure C), suggesting that surgery eradicated the remaining tumours burden. Mechanistically, the SIM regimen is thought to be a very potent inducer of DNA double-strand breaks, by cross-linking the two DNA strands. Although we know that TNBC has always been associated with higher response rate than non-TN tumours, we still do not know what is the optimal chemotherapy. It has long been suspected that some breast cancers may be very sensitive to dose-intense alkylating agent-containing protocols (Nieto and Shpall, 2009; Silver et al, 2010; Vollebergh et al, 2011). Currently, for TN tumours it is recommended to use the same chemotherapy regimen as for non-TN disease, mostly a 3-week regimen of an anthracyclin–cyclophophamide combination followed by docetaxel. However, the use of anthracyclins is still controversial in TNBC. In a combined analysis of two International Breast Cancer Study Groups (IBCSG, Trials VIII and IX), CMF regimen was shown to be likely equal to or better than FEC (Colleoni et al, 2010). On the contrary, Huober, from the German Gepar group, showed a pCR of 39% in 509 patients with TNBC treated with TAC or TAC-NX (docetaxel/doxorubicin/cyclophosphamide/vinorelbine/capecitabine),which represents the highest pCR rate reported in a large multicenter phase III trial (Huober et al, 2010; Oakman et al, 2010). Patients with TN tumours also benefit from taxanes as reported in the Gepartrio study mentioned above (Hayes et al, 2007; Huober et al, 2010). The efficacy of docetaxel was assessed in a recent metaanalysis in early breast cancers. Benefit in DFS was seen across all subgroups, including TN status ones (Jacquin et al, 2012). Small studies have suggested that platinum may be particularly effective for TNBC based on the histopathological similarities between TN breast cancers and BRCA1-mutated breast cancers (Foulkes et al, 2010). Cells with BCRA1 mutations are deficient in DNA repair mechanisms, which makes them sensitive to platinum agents. For example, pCR rate as high as 54.6% was reported in TNBC treated with a combination of docetaxel and carboplatin (Chang et al, 2010), 40% in another study combining epirubicin, cisplatin, fluorouracil followed by weekly paclitaxel (Torrisi et al, 2008) and 80% in a BRCA1-mutated population (Byrski et al, 2010). However, these data are based on small studies and need further validation in large randomised studies, specially for non-BRCA-related TNBC. Because of the high level of intratumoral VEGF in TN tumours (Linderholm et al, 2009), it was suggested that VEGF inhibitors might be well suited for TN breast cancers. Unfortunately, two large phase III trials reported conflicting results. In the study run by the German group (von Minckwitz et al, 2012a, 2012b), the addition of bevacuzimab to neoadjuvant chemotherapy significantly increased the pCR specifically in the TN breast cancer subgroup. In the NSABP-B40 study, which assessed the impact of bevacuzimab combined with neoadjuvant chemotherapy (Bear et al, 2012), the subgroup analysis revealed a more pronounced effect of bevacuzimab on hormonal receptor-positive tumours. Because of the discrepancy in these results, bevacizumab is not recommended in TNBC treated in neoaadjuvant setting. A better understanding of TN tumour biology had led to identification of potential new targets as poly-ADP ribose polymerase (PARP) inhibitors (Fong et al, 2009; Tutt et al, 2010; O’Shaughnessy et al, 2011). In tumours with BRCA1 or BRCA2 mutations (most of which are TN) (Manie et al, 2009), inhibition of PARP further compromises DNA repair leading to cell death (Andre and Pusztai, 2006; Lehmann-Che et al, 2010; Vollebergh et al, 2011). A lot of TNBC are basal-like molecular subtypes and they share similarities with BRCA1-associated breast cancer as deficiency in DNA repair pathways. Iniparib was purported to be a PARP inhibitor that showed promised results in a phase II study in patients with metastatic TN breast cancers. The phase III trial failed to show differences in PFS as well as OS. Recent data suggest that iniparib is not only structurally different from other PARP inhibitors but is also a poor inhibitor of PARP activity (Mateo et al, 2013). Triple-negative tumours belong to a molecularly heterogeneous group of tumours with different molecular alterations, future studies should aim at elucidating more refined biomarkers implicated such as TP53 mutation, BRCA1 status, basal status, CGH profile (Arnedos et al, 2012). Our data suggest that the initial response of TN tumours to the SIM regimen is followed by long-term survival and most likely definitive cures. In summary, this long-term survival analysis bears implications for the management of TN breast cancers and calls for prospective trials using this dose-dense cyclophosphamide–anthracyclin combination. We thank all the patients who participated in these studies, as well as the dedicated staff at our Breast Cancer Unit, and from the Pathology and Molecular Biology Departments, St Louis University hospital, Paris. This study was supported by grants from LNCC. Supplementary Information accompanies this paper on British Journal of Cancer website